

Sulphur Ylide-Mediated Cyclopropanation and Subsequent Spirocyclopropane Rearrangement Reactions

Qing-Song Dai,^{a,d,e} Jun-Long Li,^{c,d} Qi-Wei Wang,^{a,c,d,*} Si-Lin Yang,^d Ying-Mao Tao,^d Mei-Hao He,^d Qing-Zhu Li,^{c,d} Bo Han^{b,c,*} and Xiang Zhang^{c,d,*}

^a Chengdu Institute of Organic Chemistry, Chinese Academy of Sciences, Chengdu 610041, China. E-mail: wqw@cioc.ac.cn

^b State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. E-mail: hanbo@cdutcm.edu.cn

^c Institute for Advanced Study, Chengdu University, Chengdu 610106, China. E-mail: XZhang_CDU@hotmail.com

^d Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu 610106, PR China.

^e University of Chinese Academy of Sciences, Beijing 100049, China.

Supporting Information

Table of Contents

1. General Information.....	S2
2. Further Optimization Studies.....	S3
3. General Procedure for the Preparation of Products 3 or 5.....	S5
4. Procedure for sulphide-catalyzed (2+1) annulation.....	S34
5. Investigation for the Rearrangement of 3.....	S35
5.1 General procedure for the ring-opening rearrangement of 3.....	S35
5.2 General procedure for the oxidation/rearrangement of 9.....	S38
5.3 Proposed reaction mechanism.....	S41
6. Crystal Data and Structure Refinement.....	S42
7. References and Notes.....	S45
8. NMR Spectra.....	S46

1. General Information

General Procedures

- All reactions were performed in oven-dried or flame-dried reaction vessels, modified Schlenk flasks, or round-bottom flasks. The flasks were fitted with Teflon screw caps and reactions were conducted under an atmosphere of argon if needed. Gas-tight syringes with stainless steel needles were used to transfer air- and moisture-sensitive liquids. All moisture and/or air sensitive solid compounds were manipulated inside normal desiccators. Flash column chromatography was performed using silica gel (40–63 μm , 230–400 mesh).
- Analytical thin layer chromatography (TLC) was performed on silica gel 60 F₂₅₄ aluminum plates (Merck) containing a 254 nm fluorescent indicator. TLC plates were visualized by exposure to short wave ultraviolet light (254 nm) and I₂.
- Organic solutions were concentrated at 30–50 °C on rotary evaporators at ~10 torr followed by drying on vacuum pump at ~1 torr. Reaction temperatures are reported as the temperature of the bath surrounding the vessel unless otherwise stated.

Materials


- Commercial reagents and solvents were purchased from Adamas-beta, Aldrich Chemical Co., Alfa Aesar, Macklin, Leyan, and Energy Chemical used as received with the following exceptions: THF, Et₂O and toluene were purified by refluxing over Na-benzophenone under positive argon pressure followed by distillation.¹ The aza-dienes **1**² and sulphonium bromides **2**³ were prepared according to literature procedure.

Instrumentation

- Proton nuclear magnetic resonance (¹H NMR) spectra were recorded with JEOL-600M. Proton chemical shifts are reported in parts per million (δ scale), and are referenced using residual protium in the NMR solvent (CDCl₃: δ 7.26 (CHCl₃)). Data are reported as follows: chemical shift [multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br s = broad singlet), coupling constant(s) (Hz), integration].
- Carbon-13 nuclear magnetic resonance (¹³C NMR) spectra were recorded with JEOL 150 MHz spectrometers. Carbon chemical shifts are reported in parts per million (δ scale), and are referenced using the carbon resonances of the solvent (δ 77.0 (CHCl₃)). Data are reported as follows: chemical shift [multiplicity (if not singlet), assignment (C_q = fully substituted carbon)].
- High resolution mass spectra (HRMS) were recorded on a Waters SYNAPT G2 using an electrospray (ESI) ionisation source.
- Melting points were recorded on WRX-X-4A melting point apparatus.

2. Further Optimization Studies


Table S1. Optimisation of (2+1) Cascade ^a



Entry	Base	Solvent	Yield (%) ^b	dr ^c
1	Cs ₂ CO ₃	DCM	81	5:1
2	Cs ₂ CO ₃	toluene	50	6:1
3	Cs ₂ CO ₃	MeCN	83	6:1
4	Cs ₂ CO ₃	CHCl ₃	33	7:1
5	Cs ₂ CO ₃	THF	<5	-
6	Cs ₂ CO ₃	EtOH	75	6:1
7	Cs ₂ CO ₃	EA	74	6:1
8	K ₃ PO ₄	MeCN	62	5:1
9	K ₂ CO ₃	MeCN	87	6:1
10	NaOAc	MeCN	34	5:1
11	NaHCO ₃	MeCN	46	2:1
12	Et ₃ N	MeCN	11	6:1
13	DBU	MeCN	48	10:1
14	TMG	MeCN	<5	-
15	DBACO	MeCN	82	5:1
16 ^d	K ₂ CO ₃	MeCN	85	6:1

^a Unless otherwise noted, reactions were performed with 0.10 mmol of **1a**, 0.12 mmol of **2a** and 0.12 mmol of base in 1.0 mL of solvent at room temperature for 4 hours. ^b Isolated yield. ^c Determined by ¹H NMR analysis of the crude reaction. ^d The reaction was performed at 0 °C.

Table S2. Optimisation of (1+1+1) Cascade ^a




Entry	Lewis acid	Base	Solvent	Yield (%) ^b	dr ^c
1	BF ₃ ·OEt ₂	K ₂ CO ₃	MeCN	61	5:1
2	Mg(OTf) ₂	K ₂ CO ₃	MeCN	<5	-
3	Sc(OTf) ₃	K ₂ CO ₃	MeCN	<5	-
4	Al(OiPr) ₃	K ₂ CO ₃	MeCN	59	4:1
5	BF ₃ ·OEt ₂	K ₂ CO ₃	DCM	58	3:1
6	BF ₃ ·OEt ₂	K ₂ CO ₃	THF	<5	-
7	BF ₃ ·OEt ₂	K ₂ CO ₃	toluene	61	7:1
8	BF ₃ ·OEt ₂	K ₃ PO ₄	toluene	71	4:1
9	BF ₃ ·OEt ₂	Cs ₂ CO ₃	toluene	73	7:1
10	BF ₃ ·OEt ₂	Et ₃ N	toluene	<5	-
11	BF ₃ ·OEt ₂	DBU	toluene	<5	-
12	BF ₃ ·OEt ₂	TMG	toluene	<5	-
13	BF ₃ ·OEt ₂	DBACO	toluene	<5	-
14 ^d	BF ₃ ·OEt ₂	Cs ₂ CO ₃	toluene	23	5:1
15 ^e	BF ₃ ·OEt ₂	Cs ₂ CO ₃	toluene	36	4:1

^a Unless otherwise noted, reactions were performed with 0.12 mmol of **2a**, 0.1 mmol of **6a**, 0.15 mmol of **7a**, 0.12 mmol of base and 0.1 mmol Lewis acid in 1.0 mL of solvent at room temperature for 12 hours. ^b Isolated yield. ^c Determined by ¹H NMR analysis of the crude reaction. ^d 0.5 mL solvent was used. ^e 2 mL solvent was used.


3. General Procedure for the Preparation of Products 3 or 5

Procedure A: the direct annulation of **1** and **2** or **4**




A glass tube was charged with aza-dienes **1** (0.10 mmol), sulphonium bromides **2** (0.12 mmol) or Corey-Chaykovsky reagent **4** (0.12 mmol), K_2CO_3 (0.12 mmol) in 1 mL MeCN. The mixture was stirred at room temperature for 4 hours. Then the mixture was concentrated and purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate from 15:1 to 5:1 to afford the corresponding product **3** or **5**.

Procedure B: the three-component reaction of **2**, **6** and **7**



A glass tube was charged with sulphonium bromides **2** (0.12 mmol), iminoindoline **6** (0.10 mmol), aldehyde **7** (0.12 mmol), Cs_2CO_3 (0.12 mmol) and $BF_3 \cdot OEt_2$ (0.1 mmol) in 1 mL toluene. The mixture was stirred at room temperature for 12 hours. Then the mixture was purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate from 15:1 to 5:1 to afford the corresponding product **3**.


Procedure for large-scale synthesis of 3d



A glass tube was charged with aza-diene **1i** (20 mmol, 1.052 g), sulphonium bromide **2a** (24

mmol, 626.4 mg), K₂CO₃ (24 mmol, 331.2 mg) in 20 mL MeCN. The mixture was stirred at room temperature for 4 hours. Then the mixture was concentrated and purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate from 15:1 to 5:1 to afford the corresponding product **3i** (948.6 mg) in 90% yield as light yellow solid. The diastereomeric ratio was determined to be 9:1 by crude ¹H-NMR analysis.

N-((Z)-2-benzoyl-3-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3a



Prepared according to the *General Procedure A* to afford **3a** (42.8 mg) in 87% yield as light yellow solid, m.p. = 181 – 184 °C. The diastereomeric ratio was determined to be 6:1 by crude ¹H-NMR analysis.

Prepared according to the *General Procedure B* to afford chiral **3a** (35.9 mg) in 73% yield as light yellow solid. The diastereomeric ratio was determined to be 7:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3a:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.15 (s, 1H), 7.93 (d, *J* = 7.8 Hz, 2H), 7.55 (t, *J* = 7.2 Hz, 1H), 7.43 – 7.39 (m, 2H), 7.32 – 7.27 (m, 3H), 7.21 (t, *J* = 7.2 Hz, 1H), 7.16 (d, *J* = 7.2 Hz, 2H), 7.11 – 7.06 (m, 5H), 7.05 – 7.01 (m, 2H), 4.47 (d, *J* = 9.0 Hz, 1H), 4.25 (d, *J* = 9.0 Hz, 1H), 2.39 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 192.2, 165.6, 142.5, 140.9, 138.7, 136.5, 133.9, 131.9, 129.5, 129.1, 128.9, 128.5, 127.9, 127.5, 126.5, 126.0, 123.6, 122.0, 110.0, 43.8, 43.0, 42.3, 21.5.

HRMS (ESI) *m/z* calculated for C₃₀H₂₄N₂O₃S+Na⁺: 515.1400, found: 515.1407.

N-((Z)-2-benzoyl-3-(4-fluorophenyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3b



Prepared according to the **General Procedure A** to afford **3b** (46.4 mg) in 91% yield as white solid, m.p. = 218 – 220 °C. The diastereomeric ratio was determined to be 10:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3b:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.24 (s, 1H), 7.96 (d, *J* = 6.6 Hz, 2H), 7.58 (t, *J* = 7.2 Hz, 1H), 7.48 – 7.43 (m, 2H), 7.38 (d, *J* = 7.8 Hz, 2H), 7.27 (d, *J* = 3.0 Hz, 1H), 7.24 (t, *J* = 8.4 Hz, 1H), 7.16 (d, *J* = 8.4 Hz, 2H), 7.08 – 7.00 (m, 4H), 6.65 – 6.60 (m, 2H), 4.42 (d, *J* = 9.0 Hz, 1H), 4.18 (d, *J* = 9.0 Hz, 1H), 2.44 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 192.1, 165.0, 162.0 (d, *J* = 244.2 Hz, 1C), 143.0, 140.9, 138.5, 136.4, 134.0, 131.0 (d, *J* = 8.6 Hz, 1C), 129.1, 128.9, 128.5, 128.0, 127.6, 126.3, 123.7, 122.0, 114.7 (d, *J* = 21.6 Hz, 1C), 110.0, 43.5, 42.9, 41.4, 21.4.

HRMS (ESI) *m/z* calculated for C₃₀H₂₃FN₂O₃S+Na⁺: 533.1306, found: 533.1312.

N-((Z)-2-benzoyl-3-(4-chlorophenyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3c



Prepared according to the **General Procedure A** to afford **3c** (44.3 mg) in 84% yield as white solid, m.p. = 223 – 225 °C. The diastereomeric ratio was determined to be 11:1 by crude ¹H-NMR analysis.

Prepared according to the **General Procedure B** to afford chiral **3c** (24.2 mg) in 46% yield as white solid. The diastereomeric ratio was determined to be 7:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3c:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.21 (s, 1H), 7.96 – 7.92 (m, 2H), 7.58 – 7.54 (m, 1H), 7.46 – 7.42 (m, 2H), 7.35 (d, *J* = 8.4 Hz, 2H), 7.25 – 7.21 (m, 2H), 7.18 (d, *J* = 7.8 Hz, 2H), 7.06 – 7.00 (m, 4H), 6.90 (d, *J* = 7.8 Hz, 2H), 4.41 (d, *J* = 7.8 Hz, 1H), 4.16 (d, *J* = 9.0 Hz, 1H), 2.44 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 192.0, 165.0, 143.1, 140.9, 138.4, 136.4, 134.0, 133.4, 130.7, 130.5, 129.2, 128.9, 128.5, 128.1, 127.9, 126.1, 125.9, 123.7, 122.0, 111.0, 43.5, 42.8, 41.2, 21.6.

HRMS (ESI) *m/z* calculated for C₃₀H₂₃ClN₂O₃S+Na⁺: 549.1010(³⁵Cl), 550.1044 (³⁷Cl), found: 549.1002, 550.1050.

N-((Z)-2-benzoyl-3-(4-bromophenyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3d



Prepared according to the **General Procedure A** to afford **3d** (40.0 mg) in 70% yield as white solid, m.p. = 234 – 239 °C. The diastereomeric ratio was determined to be 7:1 by crude ¹H-NMR analysis.

Prepared according to the **General Procedure B** to afford chiral **3d** (33.7 mg) in 59% yield as white solid. The diastereomeric ratio was determined to be 6:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3d:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.25 (s, 1H), 7.95 – 7.92 (m, 2H), 7.58 – 7.53 (m, 1H), 7.46 – 7.41 (m, 2H), 7.36 (d, *J* = 8.4 Hz, 2H), 7.25 – 7.18 (m, 4H), 7.09 – 7.01 (m, 4H), 6.96 (d, *J* = 8.4 Hz, 2H), 4.40 (d, *J* = 9.0 Hz, 1H), 4.14 (d, *J* = 9.0 Hz, 1H), 2.45 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 191.9, 165.0, 143.1, 141.0, 138.4, 136.4, 134.0, 131.1, 131.0, 130.8, 129.3, 128.9, 128.5, 128.1, 126.1, 125.9, 123.7, 122.0, 121.6, 111.0, 43.5, 42.8, 41.2, 21.7.

HRMS (ESI) *m/z* calculated for C₃₀H₂₃BrN₂O₃S+Na⁺: 593.0505(⁷⁹Br), 595.0485 (⁸¹Br), found: 593.0501, 595.0474.

N-((Z)-2-benzoyl-3-(4-nitrophenyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3e



Prepared according to the **General Procedure A** to afford **3e** (41.3 mg) in 77% yield as white solid, m.p. = 232 – 234 °C. The diastereomeric ratio was determined to be 20:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3e:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.26 (s, 1H), 7.95 (d, *J* = 6.6 Hz, 2H), 7.73 – 7.69 (m, 2H), 7.59 (t, *J* = 7.2 Hz, 1H), 7.48 – 7.40 (m, 2H), 7.36 (d, *J* = 8.4 Hz, 2H), 7.25 – 7.20 (m, 4H), 7.08 – 7.02 (m, 4H), 4.44 (d, *J* = 8.4 Hz, 1H), 4.23 (d, *J* = 8.4 Hz, 1H), 2.37 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 191.5, 164.4, 146.7, 143.7, 141.1, 139.8, 138.4, 136.2, 134.2, 130.3, 129.0, 129.0, 128.6, 128.5, 125.9, 125.5, 123.9, 122.7, 122.1, 111.2, 43.2, 42.5, 40.5, 21.3.

HRMS (ESI) *m/z* calculated for C₃₀H₂₃N₃O₅S+Na⁺: 560.1251, found: 560.1248.

N-((Z)-2-benzoyl-3-(p-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3f



Prepared according to the **General Procedure A** to afford **3f** (44.5 mg) in 88% yield as light yellow solid, m.p. = 225 – 226 °C. The diastereomeric ratio was determined to be 5:1 by crude ¹H-NMR analysis.

Prepared according to the **General Procedure B** to afford chiral **3f** (27.8 mg) in 55% yield as light yellow solid. The diastereomeric ratio was determined to be 3:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3f:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.15 (s, 1H), 7.94 (d, *J* = 8.4 Hz, 2H), 7.55 (t, *J* = 7.2 Hz, 1H), 7.45 – 7.40 (m, 2H), 7.31 (d, *J* = 9.0 Hz, 2H), 7.28 (d, *J* = 7.2 Hz, 1H), 7.21 (t, *J* = 7.8 Hz, 1H), 7.09 (d, *J* = 7.2 Hz, 2H), 7.04 – 7.01 (m, 4H), 6.84 (d, *J* = 7.2 Hz, 2H), 4.45 (d, *J* = 8.4 Hz, 1H), 4.21 (d, *J* = 9.0 Hz, 1H), 2.41 (s, 3H), 2.24 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 192.3, 165.6, 142.4, 140.8, 138.7, 136.9, 136.5, 133.9, 129.4, 128.9, 128.9, 128.8, 128.5, 128.5, 127.8, 126.6, 126.1, 123.6, 122.0, 110.9, 43.9, 43.1, 42.3, 21.5, 21.2.

HRMS (ESI) *m/z* calculated for C₃₁H₂₆N₂O₃S+H⁺: 507.1737, found: 507.1744.

N-((Z)-2-benzoyl-3-(4-methoxyphenyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3g



Prepared according to the **General Procedure A** to afford **3g** (48.0 mg) in 92% yield as yellow solid, m.p. = 200 – 202 °C. The diastereomeric ratio was determined to be 5:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3g:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.19 (s, 1H), 7.94 (d, *J* = 7.8 Hz, 2H), 7.55 (t, *J* = 6.6 Hz, 1H), 7.46 – 7.41 (m, 2H), 7.32 (d, *J* = 7.8 Hz, 2H), 7.27 (d, *J* = 7.2 Hz, 1H), 7.22 – 7.18 (m, 1H), 7.09 (d, *J* = 7.8 Hz, 2H), 7.07 – 7.00 (m, 4H), 6.55 (d, *J* = 8.4 Hz, 2H), 4.45 (d, *J* = 9.0 Hz, 1H), 4.19 (d, *J* = 9.0 Hz, 1H), 3.73 (s, 3H), 2.39 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 192.3, 165.5, 158.9, 142.5, 140.8, 138.6, 136.5, 133.9, 130.6, 129.0, 128.9, 128.5, 128.1, 127.8, 126.6, 125.9, 123.7, 123.6, 122.0, 113.2, 110.8, 54.9, 43.9, 43.1, 42.2, 21.5.

HRMS (ESI) m/z calculated for $C_{31}H_{26}N_2O_4S+H^+$: 523.1686, found: 523.1692.

N-((Z)-2-benzoyl-3-(3-fluorophenyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3h



Prepared according to the *General Procedure A* to afford **3h** (38.8 mg) in 76% yield as white solid, m.p. = 204 – 208 °C. The diastereomeric ratio was determined to be 5:1 by crude 1H -NMR analysis.


NMR and HRMS data for the product 3h:

1H NMR (600 MHz, $CDCl_3$) δ (ppm): 10.12 (s, 1H), 7.93 (d, $J = 8.4$ Hz, 2H), 7.57 (t, $J = 7.2$ Hz, 1H), 7.47 – 7.41 (m, 2H), 7.38 (d, $J = 7.8$ Hz, 2H), 7.25 – 7.21 (m, 2H), 7.13 (d, $J = 7.8$ Hz, 2H), 7.06 – 6.96 (m, 3H), 6.93 (d, $J = 7.2$ Hz, 1H), 6.82 – 6.78 (m, 1H), 6.71 – 6.66 (m, 1H), 4.42 (d, $J = 9.0$ Hz, 1H), 4.19 (d, $J = 9.0$ Hz, 1H), 2.41 (s, 3H).

^{13}C NMR (150 MHz, $CDCl_3$) δ (ppm): 191.9, 165.2, 162.2 (d, $J = 244.2$ Hz, 1C), 142.8, 140.9, 138.7, 136.4, 134.5, 134.0, 129.6, 129.3 (d, $J = 7.2$ Hz, 1C),, 128.9, 128.5, 128.1, 126.1, 126.0, 125.2, 123.7, 122.1, 116.5 (d, $J = 23.1$ Hz, 1C), 114.5(d, $J = 21.6$ Hz, 1C), 110.9, 43.5, 42.8, 41.4, 21.5.

HRMS (ESI) m/z calculated for $C_{30}H_{23}FN_2O_3S+Na^+$: 533.1306, found: 533.1306.

N-((Z)-2-benzoyl-3-(3-chlorophenyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3i



Prepared according to the *General Procedure A* to afford **3i** (49.5 mg) in 94% yield as light

yellow solid, m.p. = 207 – 211 °C. The diastereomeric ratio was determined to be 9:1 by crude ¹H-NMR analysis.

Prepared according to the **General Procedure B** to afford chiral **3i** (30.0 mg) in 57% yield as light yellow solid. The diastereomeric ratio was determined to be 7:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3i:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.10 (s, 1H), 7.93 (d, *J* = 7.8 Hz, 2H), 7.57 (t, *J* = 7.8 Hz, 1H), 7.46 – 7.42 (m, 2H), 7.36 (d, *J* = 8.4 Hz, 2H), 7.25 – 7.21 (m, 2H), 7.14 (d, *J* = 7.8 Hz, 2H), 7.09 (s, 1H), 7.06 – 7.01 (m, 3H), 6.97 – 6.93 (m, 2H), 4.42 (d, *J* = 9.0 Hz, 1H), 4.18 (d, *J* = 9.0 Hz, 1H), 2.42 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 191.8, 165.1, 142.8, 140.9, 138.6, 136.4, 134.1, 134.1, 133.8, 129.5, 129.2, 129.0, 129.0, 128.5, 128.1, 127.7, 127.7, 126.0, 125.9, 123.8, 122.1, 110.9, 43.4, 42.6, 41.2, 21.5.

HRMS (ESI) m/z calculated for C₃₀H₂₃ClN₂O₃S+Na⁺: 549.1010(³⁵Cl), 550.1044 (³⁷Cl), found: 549.1013, 550.1040.

N-((Z)-2-benzoyl-3-(m-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzene sulfonamide 3j



Prepared according to the **General Procedure A** to afford **3j** (47.0 mg) in 93% yield as white solid, m.p. = 191 – 193 °C. The diastereomeric ratio was determined to be 6:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3j:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.06 (s, 1H), 7.94 (d, *J* = 7.8 Hz, 2H), 7.56 (t, *J* = 7.2 Hz, 1H), 7.46 – 7.42 (m, 2H), 7.29 – 7.25 (m, 3H), 7.23 – 7.19 (m, 1H), 7.08 (d, *J* = 8.4 Hz, 2H), 7.05 – 7.01 (m, 2H), 6.97 (d, *J* = 4.8 Hz, 2H), 6.95 (s, 1H), 6.91 – 6.87 (m, 1H), 4.47 (d, *J* = 9.0 Hz, 1H), 4.22 (d, *J* = 9.0 Hz, 1H), 2.40 (s, 3H), 2.14 (s, 3H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 192.2, 165.7, 142.4, 140.8, 138.8, 137.4, 136.6, 133.9, 131.8, 130.2, 129.0, 128.9, 128.5, 128.3, 127.9, 126.6, 126.6, 126.0, 123.7, 122.1, 110.8, 43.8, 43.0, 42.4, 21.5, 21.2.

HRMS (ESI) m/z calculated for $\text{C}_{31}\text{H}_{26}\text{N}_2\text{O}_3\text{S}+\text{Na}^+$: 529.1556, found: 529.1563.

N-((Z)-2-benzoyl-3-(2-fluorophenyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3k



Prepared according to the *General Procedure A* to afford **3k** (41.3 mg) in 81% yield as white solid, m.p. = 214 – 218 °C. The diastereomeric ratio was determined to be 20:1 by crude ^1H -NMR analysis.


NMR and HRMS data for the product 3k:

^1H NMR (600 MHz, CDCl_3) δ (ppm): 10.17 (s, 1H), 7.91 (d, $J = 7.8$ Hz, 2H), 7.55 (t, $J = 7.2$ Hz, 1H), 7.44 – 7.37 (m, 4H), 7.28 – 7.25 (m, 1H), 7.24 – 7.19 (m, 2H), 7.13 (d, $J = 7.8$ Hz, 2H), 7.06 – 6.98 (m, 3H), 6.90 (t, $J = 7.8$ Hz, 1H), 6.57 (t, $J = 9.0$ Hz, 1H), 4.33 (d, $J = 8.4$ Hz, 1H), 4.10 (d, $J = 8.4$ Hz, 1H), 2.41 (s, 3H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 192.0, 165.5, 161.5 (d, $J = 245.7$ Hz, 1C), 142.6, 141.0, 138.7, 136.5, 134.0, 131.1, 129.2, 129.1, 128.9, 128.5, 128.0, 126.2, 125.9, 123.7, 123.4 (d, $J = 2.9$ Hz, 1C), 122.1, 119.9 (d, $J = 14.4$ Hz, 1C), 114.7 (d, $J = 20.1$ Hz, 1C), 110.9, 42.8, 42.8, 35.7, 21.5.

HRMS (ESI) m/z calculated for $\text{C}_{30}\text{H}_{23}\text{FN}_2\text{O}_3\text{S}+\text{Na}^+$: 533.1306, found: 533.1306.

N-((Z)-2-benzoyl-3-(o-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3l



Prepared according to the **General Procedure A** to afford **3l** (43.5 mg) in 86% yield as yellow solid, m.p. = 178 – 182 °C. The diastereomeric ratio was determined to be 4:1 by crude ¹H-NMR analysis.

Prepared according to the **General Procedure B** to afford chiral **3l** (29.9 mg) in 59% yield as yellow solid. The diastereomeric ratio was determined to be 2:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3l:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.07 (s, 1H), 7.94 (d, *J* = 6.6 Hz, 2H), 7.56 (t, *J* = 7.2 Hz, 1H), 7.46 – 7.41 (m, 2H), 7.30 (d, *J* = 7.8 Hz, 1H), 7.25 – 7.20 (m, 4H), 7.09 (d, *J* = 8.4 Hz, 2H), 7.07 – 7.01 (m, 4H), 6.82 – 6.79 (m, 1H), 4.45 (d, *J* = 8.4 Hz, 1H), 4.05 (d, *J* = 9.0 Hz, 1H), 2.41 (s, 3H), 1.73 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 192.3, 165.6, 142.5, 140.7, 138.6, 137.6, 136.5, 133.9, 131.1, 129.6, 129.5, 129.1, 128.9, 128.5, 127.9, 127.7, 126.3, 126.0, 125.5, 123.8, 122.0, 110.9, 43.6, 43.3, 41.4, 21.5, 19.2.

HRMS (ESI) *m/z* calculated for C₃₁H₂₆N₂O₃S+Na⁺: 529.1556, found: 529.1550.

N-((Z)-2-benzoyl-3-(3,4-dimethylphenyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3m



Prepared according to the **General Procedure A** to afford **3m** (37.4 mg) in 72% yield as light yellow solid, m.p. = 219 – 223 °C. The diastereomeric ratio was determined to be 5:1 by crude ¹H-NMR analysis.

NMR and HRMS data for the product 3m:


¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.11 (s, 1H), 7.95 (d, *J* = 7.8 Hz, 2H), 7.55 (t, *J* = 7.2

Hz, 1H), 7.45 – 7.41 (m, 2H), 7.30 – 7.27 (m, 3H), 7.21 (t, $J = 7.2$ Hz, 1H), 7.08 – 7.00 (m, 4H), 6.92 – 6.87 (m, 2H), 6.80 (d, $J = 7.2$ Hz, 1H), 4.46 (d, $J = 9.0$ Hz, 1H), 4.20 (d, $J = 9.0$ Hz, 1H), 2.40 (s, 3H), 2.15 (s, 3H), 2.04 (s, 3H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 192.3, 165.7, 142.3, 140.8, 138.7, 136.6, 135.9, 135.5, 133.9, 130.7, 129.1, 128.9, 128.8, 128.5, 127.8, 126.9, 126.7, 126.0, 123.6, 122.1, 110.8, 43.9, 43.0, 42.5, 21.6, 19.5, 19.4.

HRMS (ESI) m/z calculated for $\text{C}_{32}\text{H}_{28}\text{N}_2\text{O}_3\text{S}+\text{Na}^+$: 543.1713, found: 543.1706.

N-((Z)-2-benzoyl-3-(furan-2-yl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3n



Prepared according to the *General Procedure A* to afford **3n** (36.6 mg) in 76% yield as yellow solid, m.p. = 182 – 185 °C. The diastereomeric ratio was determined to be 20:1 by crude ^1H -NMR analysis.

Prepared according to the *General Procedure B* to afford chiral **3n** (35.2 mg) in 73% yield as yellow solid. The diastereomeric ratio was determined to be 7:1 by crude ^1H -NMR analysis.


NMR and HRMS data for the product 3n:

^1H NMR (600 MHz, CDCl_3) δ (ppm): 10.15 (s, 1H), 7.89 (d, $J = 7.8$ Hz, 2H), 7.61 (d, $J = 8.4$ Hz, 2H), 7.57 – 7.52 (m, 1H), 7.43 – 7.38 (m, 2H), 7.24 – 7.18 (m, 4H), 7.05 – 7.00 (m, 3H), 6.20 (d, $J = 3.6$ Hz, 1H), 6.06 (dd, $J = 3.6, 1.8$ Hz, 1H), 4.38 (d, $J = 9.0$ Hz, 1H), 4.03 (d, $J = 9.0$ Hz, 1H), 2.42 (s, 3H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 191.4, 164.9, 146.1, 142.9, 141.9, 140.9, 138.7, 136.3, 134.0, 129.2, 128.9, 128.5, 128.1, 126.4, 125.6, 123.7, 122.0, 111.0, 110.3, 110.3, 42.9, 42.1, 34.4, 21.5.

HRMS (ESI) m/z calculated for $\text{C}_{28}\text{H}_{22}\text{N}_2\text{O}_4\text{S}+\text{Na}^+$: 505.1192, found: 505.1187.

N-((Z)-2-benzoyl-3-(thiophen-2-yl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3o



Prepared according to the **General Procedure A** to afford **3o** (40.8 mg) in 82% yield as gray solid, m.p. = 179 – 184 °C. The diastereomeric ratio was determined to be 12:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3o:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.12 (br s, 1H), 7.90 (d, *J* = 7.8 Hz, 2H), 7.55 (t, *J* = 7.8 Hz, 1H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.44 – 7.40 (m, 2H), 7.24 – 7.20 (m, 2H), 7.17 (d, *J* = 8.4 Hz, 2H), 7.03 (d, *J* = 8.4 Hz, 2H), 6.98 (d, *J* = 6.6 Hz, 1H), 6.90 (d, *J* = 4.2 Hz, 1H), 6.71 (dd, *J* = 6.4, 4.8 Hz, 1H), 4.43 (d, *J* = 8.4 Hz, 1H), 4.22 (d, *J* = 8.4 Hz, 1H), 2.41 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 191.6, 164.8, 142.7, 140.9, 138.8, 136.3, 134.5, 134.0, 129.1, 128.9, 128.5, 128.2, 128.1, 126.5, 126.3, 125.9, 125.4, 123.7, 122.0, 111.0, 44.1, 43.9, 37.0, 21.5.

HRMS (ESI) *m/z* calculated for C₂₈H₂₂N₂O₃S₂+Na⁺: 521.0964, found: 521.0966.

N-((Z)-2-benzoyl-3-(naphthalen-2-yl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3p



Prepared according to the **General Procedure A** to afford **3p** (30.9 mg) in 57% yield as light yellow solid, m.p. = 239 – 243 °C. The diastereomeric ratio was determined to be 2:1 by crude ¹H-NMR analysis.

Prepared according to the **General Procedure B** to afford chiral **3p** (26.0 mg) in 48% yield as light yellow solid. The diastereomeric ratio was determined to be 2:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3p:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.11 (s, 1H), 8.01 (d, *J* = 7.8 Hz, 2H), 7.69 (d, *J* = 7.8 Hz, 1H), 7.65 – 7.55 (m, 3H), 7.50 – 7.40 (m, 5H), 7.33 (d, *J* = 7.8 Hz, 1H), 7.25 – 7.19 (m, 2H), 7.09 – 7.02 (m, 2H), 6.95 (d, *J* = 8.4 Hz, 2H), 6.47 (d, *J* = 7.8 Hz, 2H), 4.63 (d, *J* = 9.0 Hz, 1H), 4.39 (d, *J* = 9.0 Hz, 1H), 2.16 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 192.3, 165.4, 142.2, 140.9, 138.0, 136.5, 134.0, 132.9, 132.8, 129.5, 129.0, 128.6, 128.5, 128.5, 128.0, 127.8, 127.6, 127.4, 127.3, 126.5, 126.0, 125.8, 125.3, 123.7, 122.1, 110.9, 43.9, 42.9, 42.4, 21.4.

HRMS (ESI) *m/z* calculated for C₃₄H₂₆N₂O₃S+Na⁺: 565.1556, found: 565.1554.

N-((Z)-2-benzoyl-3-phenethylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3q



Prepared according to the *General Procedure A* to afford **3q** (28.6 mg) in 55% yield as white solid, m.p. = 177 – 180 °C. The diastereomeric ratio was determined to be 20:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3q:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.06 (s, 1H), 7.89 (d, *J* = 8.4 Hz, 2H), 7.66 (d, *J* = 8.4 Hz, 2H), 7.48 (t, *J* = 7.8 Hz, 1H), 7.31 – 7.26 (m, 4H), 7.17 (t, *J* = 7.2 Hz, 1H), 7.10 (d, *J* = 7.8 Hz, 1H), 7.07 – 7.02 (m, 3H), 6.98 (t, *J* = 7.2 Hz, 1H), 6.94 (d, *J* = 7.2 Hz, 1H), 6.85 – 6.82 (m, 2H), 3.72 (d, *J* = 9.0 Hz, 1H), 2.90 – 2.84 (m, 1H), 2.61 – 2.54 (m, 1H), 2.53 – 2.47 (m, 1H), 2.43 (s, 3H), 2.41 – 2.34 (m, 1H), 2.30 – 2.22 (m, 1H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 192.4, 166.8, 143.2, 140.4, 140.3, 139.4, 136.6, 133.6, 129.5, 128.6, 128.5, 128.2, 128.2, 127.5, 126.9, 126.3, 125.7, 123.5, 122.0, 110.7, 45.4, 42.5, 38.9, 35.2, 25.6, 21.6.

HRMS (ESI) *m/z* calculated for C₃₂H₂₈N₂O₃S+Na⁺: 543.1713, found: 543.1703.

N-((Z)-2-benzoyl-6'-chloro-3-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3r



Prepared according to the **General Procedure A** to afford **3r** (33.7 mg) in 64% yield as white solid, m.p. = 234 – 236 °C. The diastereomeric ratio was determined to be 5:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3r:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.09 (s, 1H), 7.93 (d, *J* = 6.6 Hz, 2H), 7.58 (t, *J* = 7.2 Hz, 1H), 7.47 – 7.42 (m, 2H), 7.28 (d, *J* = 8.4 Hz, 2H), 7.22 (d, *J* = 9.0 Hz, 1H), 7.15 – 7.12 (m, 2H), 7.12 – 7.04 (m, 5H), 7.03 – 6.99 (m, 2H), 4.45 (d, *J* = 9.0 Hz, 1H), 4.22 (d, *J* = 8.4 Hz, 1H), 2.40 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 192.1, 165.5, 142.7, 141.9, 138.4, 136.4, 134.1, 131.6, 129.5, 129.2, 129.0, 128.5, 128.1, 127.6, 126.1, 124.9, 123.7, 123.1, 111.5, 43.4, 43.1, 42.6, 21.5.

HRMS (ESI) *m/z* calculated for C₃₀H₂₃ClN₂O₃S+Na⁺: 549.1010(³⁵Cl), 550.1044 (³⁷Cl), found: 549.1018, 550.1052.

N-((Z)-2-benzoyl-5'-methoxy-3-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3s



Prepared according to the **General Procedure A** to afford **3s** (39.2 mg) in 75% yield as white solid, m.p. = 178 – 180 °C. The diastereomeric ratio was determined to be 5:1 by crude ¹H-NMR analysis.

NMR and HRMS data for the product 3s:


¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.02 (s, 1H), 7.94 (d, *J* = 6.6 Hz, 2H), 7.56 (t, *J* = 7.8 Hz, 1H), 7.46 – 7.41 (m, 2H), 7.28 (d, *J* = 8.4 Hz, 2H), 7.16 (d, *J* = 7.2 Hz, 2H), 7.12 – 7.05 (m, 5H), 6.92 (d, *J* = 8.4 Hz, 1H), 6.89 (d, *J* = 2.4 Hz, 1H), 6.74 (d, *J* = 8.4 Hz, 1H), 4.47 (d, *J* =

9.0 Hz, 1H), 4.20 (d, $J = 9.0$ Hz, 1H), 3.76 (s, 3H), 2.39 (s, 3H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 192.1, 165.6, 156.5, 142.4, 138.9, 136.6, 134.4, 133.9, 131.9, 129.5, 129.1, 128.9, 128.5, 127.9, 127.5, 126.0, 113.4, 111.4, 108.4, 55.8, 44.0, 42.9, 42.5, 21.5.

HRMS (ESI) m/z calculated for $\text{C}_{31}\text{H}_{26}\text{N}_2\text{O}_4\text{S}+\text{Na}^+$: 545.1505, found: 545.1510.

N-((Z)-2-(4-fluorobenzoyl)-3-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3t



Prepared according to the *General Procedure A* to afford **3t** (39.8 mg) in 78% yield as light yellow solid, m.p. = 223 – 226 °C. The diastereomeric ratio was determined to be 8:1 by crude ^1H -NMR analysis.


NMR and HRMS data for the product 3t:

^1H NMR (600 MHz, CDCl_3) δ (ppm): 10.13 (s, 1H), 7.98 – 7.93 (m, 2H), 7.28 (d, $J = 8.4$ Hz, 2H), 7.25 – 7.20 (m, 2H), 7.15 (d, $J = 6.6$ Hz, 2H), 7.12 – 7.02 (m, 9H), 4.41 (d, $J = 9.0$ Hz, 1H), 4.23 (d, $J = 9.0$ Hz, 1H), 2.40 (s, 3H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 190.6, 166.2 (d, $J = 255.8$ Hz, 1C), 165.5, 142.5, 140.9, 138.6, 133.0, 131.8, 131.2 (d, $J = 10.0$ Hz, 1C), 129.5, 129.1, 128.0, 127.9, 127.5, 126.3, 126.1, 123.7, 122.0, 116.1 (d, $J = 21.6$ Hz, 1C), 111.0, 43.7, 42.9, 42.3, 21.5.

HRMS (ESI) m/z calculated for $\text{C}_{30}\text{H}_{23}\text{FN}_2\text{O}_3\text{S}+\text{Na}^+$: 533.1306, found: 533.1306.

N-((Z)-2-(4-chlorobenzoyl)-3-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3u



Prepared according to the **General Procedure A** to afford **3u** (37.9 mg) in 72% yield as white solid, m.p. = 247 – 249 °C. The diastereomeric ratio was determined to be 10:1 by crude ¹H-NMR analysis.

Prepared according to the **General Procedure B** to afford chiral **3u** (23.7 mg) in 45% yield as white solid. The diastereomeric ratio was determined to be 2:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3u:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.13 (s, 1H), 7.84 (d, *J* = 8.4 Hz, 2H), 7.34 (d, *J* = 9.0 Hz, 2H), 7.29 (d, *J* = 8.4 Hz, 2H), 7.24 – 7.21 (m, 2H), 7.15 (d, *J* = 6.6 Hz, 2H), 7.12 – 7.06 (m, 5H), 7.05 (d, *J* = 8.4 Hz, 2H), 4.40 (d, *J* = 9.0 Hz, 1H), 4.23 (d, *J* = 9.0 Hz, 1H), 2.40 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 191.0, 165.4, 142.6, 140.9, 140.5, 138.6, 134.8, 131.7, 129.8, 129.5, 129.2, 129.1, 128.1, 127.9, 127.5, 126.2, 126.1, 123.7, 121.9, 111.0, 43.7, 42.9, 42.3, 21.5.

HRMS (ESI) *m/z* calculated for C₃₀H₂₃ClN₂O₃S+Na⁺: 549.1010(³⁵Cl), 550.1044 (³⁷Cl), found: 549.1012, 550.1042.

4-methyl-N-((Z)-2-(4-methylbenzoyl)-3-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)benzenesulfonamide 3v



Prepared according to the **General Procedure A** to afford **3v** (38.0 mg) in 75% yield as light yellow solid, m.p. = 226 – 228 °C. The diastereomeric ratio was determined to be 2:1 by crude ¹H-NMR analysis.

Prepared according to the **General Procedure B** to afford chiral **3v** (24.3 mg) in 48% yield as light yellow solid. The diastereomeric ratio was determined to be 2:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3v:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.10 (s, 1H), 7.82 (d, *J* = 8.4 Hz, 2H), 7.30 – 7.26 (m, 3H), 7.22 – 7.14 (m, 5H), 7.10 – 7.06 (m, 5H), 7.05 – 7.01 (m, 2H), 4.44 (d, *J* = 9.0 Hz, 1H), 4.24 (d, *J* = 9.0 Hz, 1H), 2.39 (s, 3H), 2.37 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 191.6, 165.7, 145.0, 142.5, 140.8, 138.7, 134.1, 132.0, 129.6, 129.1, 128.6, 127.9, 127.8, 127.4, 126.6, 126.1, 123.6, 122.1, 110.9, 43.6, 43.1, 42.3, 21.7, 21.5.

HRMS (ESI) *m/z* calculated for C₃₁H₂₆N₂O₃S+Na⁺: 529.1556, found: 529.1560.

N-((Z)-2-(4-methoxybenzoyl)-3-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3w



Prepared according to the **General Procedure A** to afford **3w** (44.4 mg) in 85% yield as light yellow solid, m.p. = 233 – 236 °C. The diastereomeric ratio was determined to be 3:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3w:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.07 (s, 1H), 7.91 (d, *J* = 9.0 Hz, 2H), 7.28 – 7.27 (m, 3H), 7.23 – 7.19 (m, 1H), 7.17 – 7.14 (m, 2H), 7.10 – 7.06 (m, 5H), 7.05 – 7.00 (m, 2H), 6.87 (d, *J* = 9.0 Hz, 2H), 4.42 (d, *J* = 9.0 Hz, 1H), 4.23 (d, *J* = 9.0 Hz, 1H), 3.83 (s, 3H), 2.39 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 190.3, 165.8, 164.2, 142.5, 140.8, 138.7, 132.1, 130.9, 129.7, 129.5, 129.1, 127.9, 127.8, 127.4, 126.7, 126.0, 123.6, 122.1, 114.1, 110.8, 55.5, 43.5, 43.0, 42.3, 21.5.

HRMS (ESI) m/z calculated for $C_{31}H_{26}N_2O_4S+Na^+$: 545.1505, found: 545.1511.

N-((Z)-2-(3-chlorobenzoyl)-3-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3x



Prepared according to the *General Procedure A* to afford **3x** (28.5 mg) in 54% yield as light yellow solid, m.p. = 237 – 240 °C. The diastereomeric ratio was determined to be 20:1 by crude 1H -NMR analysis.

Prepared according to the *General Procedure B* to afford chiral **3x** (27.4 mg) in 52% yield as light yellow solid. The diastereomeric ratio was determined to be 7:1 by crude 1H -NMR analysis.


NMR and HRMS data for the product 3x:

1H NMR (600 MHz, $CDCl_3$) δ (ppm): 10.09 (s, 1H), 7.95 – 7.93 (m, 1H), 7.79 – 7.75 (m, 1H), 7.54 – 7.50 (m, 1H), 7.36 (t, $J = 7.8$ Hz, 1H), 7.29 (d, $J = 8.4$ Hz, 2H), 7.27 – 7.22 (m, 2H), 7.15 (d, $J = 6.6$ Hz, 2H), 7.11 – 7.02 (m, 7H), 4.40 (d, $J = 8.4$ Hz, 1H), 4.24 (d, $J = 8.4$ Hz, 1H), 2.39 (s, 3H).

^{13}C NMR (150 MHz, $CDCl_3$) δ (ppm): 191.1, 165.3, 142.6, 140.9, 138.6, 138.0, 135.3, 133.9, 131.7, 130.3, 129.5, 129.1, 128.3, 128.1, 128.0, 127.6, 126.8, 126.2, 126.1, 123.7, 122.0, 111.0, 43.9, 42.9, 42.4, 21.5.

HRMS (ESI) m/z calculated for $C_{30}H_{23}ClN_2O_3S+Na^+$: 549.1010(^{35}Cl), 550.1044 (^{37}Cl), found: 549.1016, 550.1048.

N-((Z)-2-(3-methoxybenzoyl)-3-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3y



Prepared according to the **General Procedure A** to afford **3y** (45.4 mg) in 87% yield as white solid, m.p. = 189 – 194 °C. The diastereomeric ratio was determined to be 6:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3y:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.07 (s, 1H), 7.50 (d, *J* = 7.8 Hz, 1H), 7.47 – 7.46 (m, 1H), 7.33 – 7.27 (m, 4H), 7.24 – 7.20 (m, 1H), 7.16 (d, *J* = 6.6 Hz, 2H), 7.11 – 7.07 (m, 6H), 7.05 – 7.01 (m, 2H), 4.46 (d, *J* = 9.0 Hz, 1H), 4.24 (d, *J* = 9.0 Hz, 1H), 3.82 (s, 3H), 2.39 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 192.0, 165.6, 159.9, 142.5, 140.9, 138.7, 137.8, 131.9, 129.9, 129.5, 129.1, 127.9, 127.5, 126.4, 126.0, 123.7, 122.0, 121.3, 121.0, 111.9, 110.9, 55.4, 43.8, 43.4, 42.4, 21.5.

HRMS (ESI) *m/z* calculated for C₃₁H₂₆N₂O₄S+Na⁺: 545.1505, found: 545.1504.

N-((Z)-2-(2-chlorobenzoyl)-3-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3z



Prepared according to the **General Procedure A** to afford **3z** (34.8 mg) in 66% yield as white solid, m.p. = 200 – 204 °C. The diastereomeric ratio was determined to be 20:1 by crude ¹H-NMR analysis.

NMR and HRMS data for the product 3z:


¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.08 (s, 1H), 7.49 – 7.46 (m, 2H), 7.42 – 7.35 (m, 2H), 7.31 – 7.27 (m, 2H), 7.25 (d, *J* = 8.4 Hz, 2H), 7.17 – 7.14 (m, 2H), 7.11 – 7.04 (m, 7H), 4.32 (d, *J* = 9.0 Hz, 1H), 4.30 (d, *J* = 8.4 Hz, 1H), 2.38 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 194.2, 165.5, 142.4, 141.1, 138.7, 138.1, 132.9, 132.3,

131.8, 130.9, 130.1, 129.5, 129.0, 128.1, 127.9, 127.4, 127.1, 126.4, 126.1, 123.6, 122.8, 110.9, 47.0, 45.4, 42.9, 21.5.

HRMS (ESI) m/z calculated for $C_{30}H_{23}ClN_2O_3S+Na^+$: 549.1010(^{35}Cl), 550.1044 (^{37}Cl), found: 549.1018, 550.1037.

4-methyl-N-((Z)-2-(2-methylbenzoyl)-3-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene) benzenesulfonamide 3aa



Prepared according to the *General Procedure A* to afford **3aa** (45.0 mg) in 89% yield as light yellow solid, m.p. = 214 – 215 °C. The diastereomeric ratio was determined to be 18:1 by crude 1H -NMR analysis.

Prepared according to the *General Procedure B* to afford chiral **3aa** (21.8 mg) in 43% yield as light yellow solid. The diastereomeric ratio was determined to be 2:1 by crude 1H -NMR analysis.


NMR and HRMS data for the product 3aa:

1H NMR (600 MHz, $CDCl_3$) δ (ppm): 10.12 (s, 1H), 7.56 (d, $J = 7.2$ Hz, 1H), 7.40 – 7.34 (m, 2H), 7.28 – 7.19 (m, 5H), 7.17 – 7.14 (m, 2H), 7.11 – 7.04 (m, 7H), 4.30 (d, $J = 9.0$ Hz, 1H), 4.26 (d, $J = 9.0$ Hz, 1H), 2.49 (s, 3H), 2.39 (s, 3H).

^{13}C NMR (150 MHz, $CDCl_3$) δ (ppm): 195.1, 165.5, 142.5, 140.9, 138.9, 138.7, 137.1, 132.3, 132.0, 131.9, 129.6, 129.4, 129.1, 128.0, 127.9, 127.4, 126.5, 126.2, 126.0, 123.6, 122.5, 110.9, 45.7, 44.4, 42.6, 21.5, 21.3.

HRMS (ESI) m/z calculated for $C_{31}H_{26}N_2O_3S+Na^+$: 529.1556, found: 529.1552.

N-((Z)-2-(furan-2-carbonyl)-3-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3ab



Prepared according to the **General Procedure A** to afford **3ab** (36.2 mg) in 75% yield as white solid, m.p. = 198 – 199 °C. The diastereomeric ratio was determined to be 5:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 3ab:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.11 (s, 1H), 7.60 (d, *J* = 1.2 Hz, 1H), 7.45 (d, *J* = 7.2 Hz, 1H), 7.29 (d, *J* = 3.6 Hz, 1H), 7.27 – 7.21 (m, 3H), 7.15 (d, *J* = 6.6 Hz, 2H), 7.11 – 7.05 (m, 6H), 7.04 (d, *J* = 7.8 Hz, 1H), 6.51 (dd, *J* = 3.6, 1.2 Hz, 1H), 4.37 (d, *J* = 9.0 Hz, 1H), 4.21 (d, *J* = 9.0 Hz, 1H), 2.38 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 180.4, 165.6, 152.5, 147.6, 142.4, 141.0, 138.7, 131.8, 129.5, 129.0, 127.9, 127.9, 127.4, 126.4, 126.0, 123.6, 122.7, 119.1, 112.7, 110.9, 44.1, 42.8, 41.9, 21.4.

HRMS (ESI) m/z calculated for C₂₈H₂₂N₂O₄S+Na⁺: 505.1192, found: 505.1195.

4-methyl-N-((Z)-2-phenyl-3-(thiophene-2-carbonyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)benzenesulfonamide 3ac



Prepared according to the **General Procedure A** to afford **3ac** (44.3 mg) in 89% yield as light yellow solid, m.p. = 197 – 200 °C. The diastereomeric ratio was determined to be 4:1 by crude ¹H-NMR analysis.

Prepared according to the **General Procedure B** to afford chiral **3ac** (34.4 mg) in 69% yield as light yellow solid. The diastereomeric ratio was determined to be 4:1 by crude ¹H-NMR analysis.

NMR and HRMS data for the product 3ac:


¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.12 (s, 1H), 7.76 (d, *J* = 3.0 Hz, 1H), 7.64 (d, *J* = 4.8

Hz, 1H), 7.38 (d, $J = 7.8$ Hz, 1H), 7.28 (d, $J = 8.4$ Hz, 2H), 7.23 (t, $J = 7.8$ Hz, 1H), 7.15 (d, $J = 6.6$ Hz, 2H), 7.11 – 7.05 (m, 8H), 4.37 (d, $J = 9.0$ Hz, 1H), 4.21 (d, $J = 9.0$ Hz, 1H), 2.39 (s, 3H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 184.6, 165.6, 143.9, 142.5, 141.0, 138.7, 135.1, 133.5, 131.8, 129.5, 129.1, 128.6, 127.9, 127.5, 126.4, 126.0, 123.7, 122.4, 110.9, 43.9, 43.7, 42.3, 21.5.

HRMS (ESI) m/z calculated for $\text{C}_{28}\text{H}_{22}\text{N}_2\text{O}_3\text{S}_2+\text{Na}^+$: 521.0964, found: 521.0967.

N-((Z)-2-(1-naphthoyl)-3-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3ad



Prepared according to the *General Procedure A* to afford **3ad** (33.1 mg) in 61% yield as white solid, m.p. = 219 – 221 °C. The diastereomeric ratio was determined to be 20:1 by crude ^1H -NMR analysis.


NMR and HRMS data for the product 3ad:

^1H NMR (600 MHz, CDCl_3) δ (ppm): 10.16 (s, 1H), 8.78 (d, $J = 8.4$ Hz, 1H), 7.97 (d, $J = 7.8$ Hz, 1H), 7.85 (d, $J = 7.8$ Hz, 1H), 7.83 (d, $J = 6.0$ Hz, 1H), 7.65 – 7.60 (m, 1H), 7.55 (t, $J = 7.8$ Hz, 1H), 7.46 (d, $J = 7.8$ Hz, 1H), 7.41 (t, $J = 7.8$ Hz, 1H), 7.28 (d, $J = 9.0$ Hz, 2H), 7.24 (t, $J = 7.8$ Hz, 1H), 7.19 (d, $J = 7.8$ Hz, 2H), 7.12 – 7.02 (m, 7H), 4.47 (d, $J = 9.0$ Hz, 1H), 4.37 (d, $J = 8.4$ Hz, 1H), 2.39 (s, 3H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 194.7, 165.5, 142.5, 141.0, 138.7, 134.4, 134.0, 133.9, 131.9, 130.3, 129.7, 129.6, 129.1, 128.6, 128.5, 128.0, 127.9, 127.5, 126.7, 126.6, 126.1, 125.5, 124.6, 123.7, 122.6, 110.9, 46.0, 44.7, 42.7, 21.5.

HRMS (ESI) m/z calculated for $\text{C}_{34}\text{H}_{26}\text{N}_2\text{O}_3\text{S}+\text{Na}^+$: 565.1556, found: 565.1553.

N-((Z)-2-(2-naphthoyl)-3-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 3ae



Prepared according to the **General Procedure A** to afford **3ae** (45.0 mg) in 83% yield as light yellow solid, m.p. = 242 – 244 °C. The diastereomeric ratio was determined to be 6:1 by crude ¹H-NMR analysis.

Prepared according to the **General Procedure B** to afford chiral **3ae** (22.8 mg) in 42% yield as light yellow solid. The diastereomeric ratio was determined to be 4:1 by crude ¹H-NMR analysis.

NMR and HRMS data for the product 3ae:


¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.20 (s, 1H), 8.44 (s, 1H), 7.99 – 7.96 (m, 1H), 7.86 (d, *J* = 8.4 Hz, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.56 (t, *J* = 7.2 Hz, 1H), 7.48 (d, *J* = 7.8 Hz, 1H), 7.37 – 7.31 (m, 3H), 7.23 – 7.17 (m, 3H), 7.15 – 7.08 (m, 5H), 7.07 – 7.02 (m, 2H), 4.64 (d, *J* = 9.0 Hz, 1H), 4.32 (d, *J* = 9.0 Hz, 1H), 2.41 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 191.9, 165.7, 142.5, 141.0, 138.8, 135.8, 133.8, 132.3, 132.0, 130.8, 129.9, 129.6, 129.1, 128.9, 128.8, 127.9, 127.6, 127.5, 126.9, 126.5, 126.1, 123.6, 123.6, 122.0, 111.0, 43.9, 43.4, 42.5, 21.5.

HRMS (ESI) m/z calculated for C₃₄H₂₆N₂O₃S+Na⁺: 565.1556, found: 565.1557.

4-methyl-N-((Z)-2-phenylspiro[cyclopropane-1,3'-indolin]-2'-ylidene)benzenesulfonamide

5a



Prepared according to the **General Procedure A** to afford **5a** (34.1 mg) in 88% yield as light yellow solid, m.p. = 99 – 103 °C. The diastereomeric ratio was determined to be >20:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 5a:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.17 (s, 1H), 7.88 (d, *J* = 7.8 Hz, 2H), 7.31 – 7.26 (m, 5H), 7.16 – 7.11 (m, 3H), 7.07 (d, *J* = 7.8 Hz, 1H), 6.72 (t, *J* = 7.8 Hz, 1H), 5.97 (d, *J* = 7.2 Hz, 1H), 3.46 (t, *J* = 9.0 Hz, 1H), 2.42 (s, 3H), 2.29 (dd, *J* = 7.8, 4.8 Hz, 1H), 2.16 (dd, *J* = 8.4, 4.8 Hz, 1H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 170.4, 143.0, 140.9, 139.4, 134.3, 129.9, 129.4, 128.4, 127.8, 127.7, 127.0, 126.3, 122.8, 120.8, 110.8, 39.6, 36.7, 25.6, 21.5.

HRMS (ESI) *m/z* calculated for C₂₃H₂₀N₂O₂S+Na⁺: 411.1138, found: 411.1139.

N-((Z)-2-(4-chlorophenyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 5b



Prepared according to the *General Procedure A* to afford **5b** (35.9 mg) in 85% yield as light yellow solid, m.p. = 192 – 196 °C. The diastereomeric ratio was determined to be >20:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 5b:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.15 (s, 1H), 7.87 (d, *J* = 9.0 Hz, 2H), 7.30 (d, *J* = 7.8 Hz, 2H), 7.27 – 7.24 (m, 2H), 7.16 (t, *J* = 7.8 Hz, 1H), 7.09 – 7.04 (m, 3H), 6.78 (t, *J* = 7.2 Hz, 1H), 5.97 (d, *J* = 7.8 Hz, 1H), 3.38 (t, *J* = 9.0 Hz, 1H), 2.42 (s, 3H), 2.28 (dd, *J* = 8.4, 4.8 Hz, 1H), 2.09 (dd, *J* = 8.4, 4.8 Hz, 1H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 170.1, 143.1, 141.0, 139.2, 133.7, 132.9, 131.3, 129.4, 128.7, 127.4, 127.2, 126.3, 122.9, 120.8, 111.0, 38.6, 36.6, 25.5, 21.5.

HRMS (ESI) *m/z* calculated for C₂₃H₁₉ClN₂O₂S+Na⁺: 445.0748(³⁵Cl), 447.0718 (³⁷Cl), found: 445.0743, 447.0715.

4-methyl-N-((Z)-2-(p-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)benzenesulfonamide 5c



Prepared according to the **General Procedure A** to afford **5c** (31.0 mg) in 77% yield as light yellow solid, m.p. = 116 – 120 °C. The diastereomeric ratio was determined to be >20:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 5c:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.15 (s, 1H), 7.88 (d, *J* = 8.4 Hz, 2H), 7.29 (d, *J* = 7.2 Hz, 2H), 7.16 – 7.11 (m, 1H), 7.09 – 7.04 (m, 3H), 7.00 (d, *J* = 8.4 Hz, 2H), 6.74 (t, *J* = 7.8 Hz, 1H), 6.01 (d, *J* = 7.2 Hz, 1H), 3.42 (t, *J* = 7.8 Hz, 1H), 2.42 (s, 3H), 2.32 (s, 3H), 2.27 (dd, *J* = 9.0, 4.2 Hz, 1H), 2.14 (dd, *J* = 7.8, 3.6 Hz, 1H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 170.5, 142.9, 140.9, 139.4, 137.5, 131.2, 129.7, 129.4, 129.1, 127.9, 126.9, 126.3, 122.8, 120.9, 110.8, 39.6, 36.8, 25.8, 21.5, 21.2.

HRMS (ESI) m/z calculated for C₂₄H₂₂N₂O₂S+Na⁺:425.1294, found: 425.1293.

N-((Z)-2-(3-chlorophenyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 5d



Prepared according to the **General Procedure A** to afford **5d** (37.6 mg) in 89% yield as light yellow solid, m.p. = 182 – 185 °C. The diastereomeric ratio was determined to be >20:1 by crude ¹H-NMR analysis.

NMR and HRMS data for the product 5d:


¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.17 (s, 1H), 7.88 (d, *J* = 7.8 Hz, 2H), 7.30 (d, *J* = 8.4 Hz, 2H), 7.25 – 7.23 (m, 1H), 7.22 – 7.14 (m, 3H), 7.08 (d, *J* = 7.8 Hz, 1H), 6.98 (d, *J* = 7.2 Hz, 1H), 6.77 (t, *J* = 7.2 Hz, 1H), 6.00 (d, *J* = 7.8 Hz, 1H), 3.39 (t, *J* = 9.0 Hz, 1H), 2.42 (s, 3H),

2.27 (dd, $J = 9.6, 4.8$ Hz, 1H), 2.11 (dd, $J = 9.0, 4.8$ Hz, 1H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 170.0, 143.1, 141.0, 139.2, 136.4, 134.3, 129.8, 129.7, 129.5, 128.3, 128.0, 127.3, 126.3, 122.9, 120.8, 111.0, 38.6, 36.6, 25.3, 21.5.

HRMS (ESI) m/z calculated for $\text{C}_{23}\text{H}_{19}\text{ClN}_2\text{O}_2\text{S}+\text{Na}^+$: 445.0748(^{35}Cl), 447.0718 (^{37}Cl), found: 445.0740, 447.0721.

4-methyl-N-((Z)-2-(m-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)benzenesulfonamide 5e



Prepared according to the *General Procedure A* to afford **5e** (32.6 mg) in 81% yield as light yellow solid, m.p. = 140 – 142 °C. The diastereomeric ratio was determined to be >20:1 by crude ^1H -NMR analysis.


NMR and HRMS data for the product 5e:

^1H NMR (600 MHz, CDCl_3) δ (ppm): 10.17 (s, 1H), 7.89 (d, $J = 8.4$ Hz, 2H), 7.29 (d, $J = 8.4$ Hz, 2H), 7.18 – 7.11 (m, 2H), 7.07 (d, $J = 7.8$ Hz, 2H), 6.97 – 6.89 (m, 2H), 6.74 (t, $J = 7.8$ Hz, 1H), 6.01 (d, $J = 7.2$ Hz, 1H), 3.43 (t, $J = 9.0$ Hz, 1H), 2.42 (s, 3H), 2.28 (s, 3H), 2.26 (dd, $J = 9.6, 4.8$ Hz, 1H), 2.15 (dd, $J = 8.4, 4.2$ Hz, 1H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 170.5, 142.9, 140.9, 139.4, 138.1, 134.1, 130.6, 129.4, 128.5, 128.3, 127.9, 126.9, 126.9, 126.3, 122.8, 120.9, 110.8, 39.7, 36.8, 25.7, 21.5, 21.3.

HRMS (ESI) m/z calculated for $\text{C}_{24}\text{H}_{22}\text{N}_2\text{O}_2\text{S}+\text{Na}^+$: 425.1294, found: 425.1295.

N-((Z)-2-(2-chlorophenyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 5f



Prepared according to the *General Procedure A* to afford **5f** (32.1 mg) in 76% yield as gray solid, m.p. = 174 – 177 °C. The diastereomeric ratio was determined to be >20:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 5f:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.20 (s, 1H), 7.88 (d, *J* = 7.8 Hz, 2H), 7.40 (d, *J* = 6.6 Hz, 1H), 7.33 – 7.27 (m, 3H), 7.24 – 7.17 (m, 2H), 7.16 – 7.12 (m, 1H), 7.07 – 7.04 (m, 1H), 6.69 (t, *J* = 7.8 Hz, 1H), 5.88 (d, *J* = 7.8 Hz, 1H), 3.26 (t, *J* = 9.0 Hz, 1H), 2.42 (dd, *J* = 9.6, 4.8 Hz, 1H), 2.40 (s, 3H), 2.18 (dd, *J* = 9.0, 4.8 Hz, 1H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 170.4, 143.0, 141.1, 139.4, 137.0, 133.0, 130.0, 129.4, 129.2, 127.2, 126.7, 126.2, 122.7, 119.5, 110.9, 38.7, 36.8, 24.4, 21.5.

HRMS (ESI) *m/z* calculated for C₂₃H₁₉ClN₂O₂S+Na⁺: 445.0748(³⁵Cl), 447.0718 (³⁷Cl), found: 445.0740, 447.0717.

4-methyl-N-((Z)-2-(o-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)benzenesulfonamide 5g



Prepared according to the *General Procedure A* to afford **5g** (30.2 mg) in 75% yield as light yellow solid, m.p. = 173 – 176 °C. The diastereomeric ratio was determined to be >20:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 5g:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.21 (s, 1H), 7.87 (d, *J* = 8.4 Hz, 2H), 7.32 (d, *J* = 7.2 Hz, 1H), 7.27 (d, *J* = 8.4 Hz, 2H), 7.22 (t, *J* = 7.2 Hz, 1H), 7.19 – 7.15 (m, 1H), 7.14 – 7.10 (m, 1H), 7.05 (d, *J* = 7.8 Hz, 1H), 6.97 (d, *J* = 7.8 Hz, 1H), 6.67 (t, *J* = 7.2 Hz, 1H), 5.87 (d, *J* = 7.8 Hz, 1H), 3.20 (t, *J* = 9.0 Hz, 1H), 2.40 (s, 3H), 2.36 (dd, *J* = 9.6, 4.8 Hz, 1H), 2.21 (dd, *J* = 8.4, 4.2 Hz, 1H), 1.55 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 170.5, 143.0, 140.6, 139.5, 139.1, 133.1, 129.9, 129.4, 128.4, 128.0, 127.7, 127.0, 126.2, 125.8, 122.8, 120.0, 110.8, 39.3, 36.6, 25.2, 21.5, 18.8.

HRMS (ESI) *m/z* calculated for C₂₄H₂₂N₂O₂S+Na⁺: 425.1294, found: 425.1301.

N-((Z)-2-(furan-2-yl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)-4-methylbenzenesulfonamide 5h



Prepared according to the **General Procedure A** to afford **5h** (29.9 mg) in 79% yield as red solid, m.p. = 140 – 144 °C. The diastereomeric ratio was determined to be >20:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 5h:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.07 (s, 1H), 7.86 (d, *J* = 7.8 Hz, 2H), 7.32 – 7.27 (m, 3H), 7.19 (t, *J* = 7.2 Hz, 1H), 7.05 (d, *J* = 7.8 Hz, 1H), 6.87 (t, *J* = 7.8 Hz, 1H), 6.51 (d, *J* = 7.8 Hz, 1H), 6.34 (dd, *J* = 3.6, 1.8 Hz, 1H), 6.28 (d, *J* = 3.6 Hz, 1H), 3.22 (t, *J* = 9.0 Hz, 1H), 2.42 (s, 3H), 2.32 – 2.25 (m, 2H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 169.3, 149.3, 143.1, 142.3, 141.0, 139.2, 129.4, 127.5, 127.4, 126.3, 123.2, 120.2, 110.9, 110.7, 110.0, 37.3, 32.4, 24.0, 21.5.

HRMS (ESI) *m/z* calculated for C₂₁H₁₈N₂O₃S+Na⁺: 401.0930, found: 401.0928.

4-methyl-N-((Z)-2-(thiophen-2-yl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)benzenesulfonamide 5i



Prepared according to the **General Procedure A** to afford **5i** (29.2 mg) in 74% yield as white solid, m.p. = 134 – 137 °C. The diastereomeric ratio was determined to be >20:1 by crude ¹H-NMR analysis.

NMR and HRMS data for the product 5i:


¹H NMR (600 MHz, CDCl₃) δ (ppm): 10.12 (s, 1H), 7.87 (d, *J* = 7.8 Hz, 2H), 7.30 (d, *J* = 7.8 Hz, 2H), 7.21 – 7.16 (m, 2H), 7.07 (d, *J* = 7.8 Hz, 1H), 6.95 (dd, *J* = 4.8, 3.6 Hz, 1H), 6.90 –

6.87 (m, 1H), 6.81 (t, $J = 7.8$ Hz, 1H), 6.25 (d, $J = 7.8$ Hz, 1H), 3.39 (t, $J = 9.0$ Hz, 1H), 2.42 (s, 3H), 2.34 (dd, $J = 9.0, 4.8$ Hz, 1H), 2.18 (dd, $J = 7.8, 4.8$ Hz, 1H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 169.6, 143.1, 141.0, 139.2, 138.0, 129.4, 127.9, 127.3, 127.2, 126.8, 126.3, 125.7, 123.0, 120.4, 110.9, 37.5, 33.8, 26.6, 21.5.

HRMS (ESI) m/z calculated for $\text{C}_{21}\text{H}_{18}\text{N}_2\text{O}_2\text{S}_2+\text{Na}^+$: 417.0702, found: 419.0699.

4-methyl-N-((Z)-2-(naphthalen-2-yl)spiro[cyclopropane-1,3'-indolin]-2'-ylidene)benzenesulfonamide 5j



Prepared according to the *General Procedure A* to afford **5j** (31.5 mg) in 72% yield as light yellow solid, m.p. = 189 – 191 °C. The diastereomeric ratio was determined to be >20:1 by crude ^1H -NMR analysis.


NMR and HRMS data for the product 5j:

^1H NMR (600 MHz, CDCl_3) δ (ppm): 10.21(s, 1H), 7.91 (d, $J = 7.8$ Hz, 2H), 7.82 – 7.78 (m, 2H), 7.73 – 7.67 (m, 2H), 7.51 – 7.44 (m, 2H), 7.31 (d, $J = 8.4$ Hz, 2H), 7.13 – 7.05 (m, 3H), 6.62 (t, $J = 7.8$ Hz, 1H), 5.96 (d, $J = 7.2$ Hz, 1H), 3.60 (t, $J = 9.0$ Hz, 1H), 2.43 (s, 3H), 2.37 (dd, $J = 9.0, 4.8$ Hz, 1H), 2.30 (dd, $J = 7.8, 4.8$ Hz, 1H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 170.4, 143.0, 140.9, 139.4, 133.1, 132.8, 132.0, 129.4, 128.3, 128.2, 128.0, 127.8, 127.7, 127.7, 127.0, 126.3, 126.2, 122.9, 120.7, 110.9, 39.8, 36.8, 25.7, 21.5.

HRMS (ESI) m/z calculated for $\text{C}_{27}\text{H}_{22}\text{N}_2\text{O}_2\text{S}+\text{Na}^+$:461.1294, found: 461.1294.


4. Procedure for sulphide-catalyzed (2+1) annulation



A glass reaction tube was charged with iminoindole **1a** (0.1 mmol), bromide **8** (0.15 mmol), thiophane (0.02 mmol) and K₂CO₃ (0.12 mmol) in 1.0 mL MeCN. The mixture was stirred at room temperature for 12 hours. Then the mixture was concentrated, and purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate from 20:1 to 15:1 to afford the corresponding product **3a** (30.5 mg) in 62% yield as light yellow solid. The diastereomeric ratio was determined to be 1:1 by crude ¹H-NMR analysis.


5. Investigation for the Rearrangement of 3

5.1 General procedure for the ring-opening rearrangement of 3



A Schlenk tube was charged with **3** (0.1 mmol), $\text{BF}_3 \cdot \text{OEt}_2$ **2** (1 mmol), H_2O (0.1 mmol) in 1 mL DCM. The mixture was stirred at 60 °C for 12 hours. Then the mixture was purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate from 15:1 to 10:1 to afford the corresponding product **9**.

phenyl(2-phenyl-1-tosyl-1,2,3,8-tetrahydropyrrolo[2,3-b]indol-3-yl)methanone 9a



Prepared according to the general procedure to afford **9a** (19.7 mg) in 40% yield as light yellow solid, m.p. = 210 – 214 °C. The diastereomeric ratio was determined to be >20:1 by crude $^1\text{H-NMR}$ analysis.

NMR and HRMS data for the product 9a:


$^1\text{H NMR}$ (600 MHz, CDCl_3) δ (ppm): 8.86 (s, 1H), 7.87 (d, $J = 7.8$ Hz, 2H), 7.66 – 7.60 (m, 3H), 7.50 – 7.45 (m, 2H), 7.41 – 7.36 (m, 4H), 7.35 – 7.29 (m, 4H), 7.04 (t, $J = 7.8$ Hz, 1H), 6.86 (t, $J = 8.4$ Hz, 1H), 6.57 (d, $J = 7.2$ Hz, 1H), 5.90 (d, $J = 3.6$ Hz, 1H), 4.98 (d, $J = 4.8$ Hz, 1H), 2.46 (s, 3H).

$^{13}\text{C NMR}$ (150 MHz, CDCl_3) δ (ppm): 195.6, 144.9, 141.4, 141.2, 137.8, 136.2, 133.7, 132.0, 130.0, 128.9, 128.7, 128.7, 128.3, 128.0, 126.4, 123.4, 120.8, 120.7, 117.7, 111.9, 99.5, 72.2, 56.4, 21.7.

HRMS (ESI) m/z calculated for $\text{C}_{30}\text{H}_{24}\text{N}_2\text{O}_3\text{S} + \text{Na}^+$: 515.1400, found: 515.1396.

(2-(4-chlorophenyl)-1-tosyl-1,2,3,8-tetrahydropyrrolo[2,3-b]indol-3-yl)(phenyl)methanone

9b



Prepared according to the general procedure to afford **9b** (18.4 mg) in 35% yield as yellow solid, m.p. = 194 – 196 °C. The diastereomeric ratio was determined to be >20:1 by crude ¹H-NMR analysis.


NMR and HRMS data for the product 9b:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 8.83 (s, 1H), 7.87 (d, *J* = 7.8 Hz, 2H), 7.66 – 7.60 (m, 3H), 7.52 – 7.46 (m, 2H), 7.35 – 7.29 (m, 7H), 7.05 (t, *J* = 7.8 Hz, 1H), 6.86 (t, *J* = 7.8 Hz, 1H), 6.55 (d, *J* = 7.8 Hz, 1H), 5.86 (d, *J* = 4.8 Hz, 1H), 4.93 (d, *J* = 4.8 Hz, 1H), 2.46 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 195.4, 145.1, 141.2, 139.6, 137.8, 136.1, 134.1, 133.8, 131.8, 130.1, 129.1, 128.8, 128.7, 128.0, 127.9, 123.2, 120.9, 117.7, 111.9, 99.3, 71.5, 56.3, 21.7.

HRMS (ESI) m/z calculated for C₃₀H₂₃ClN₂O₃S+Na⁺: 549.1010(³⁵Cl), 550.1044 (³⁷Cl), found: 549.1018, 550.1054.

phenyl(2-(p-tolyl)-1-tosyl-1,2,3,8-tetrahydropyrrolo[2,3-b]indol-3-yl)methanone 9c



Prepared according to the general procedure to afford **9c** (16.2 mg) in 32% yield as yellow solid, m.p. = 205 – 208 °C. The diastereomeric ratio was determined to be >20:1 by crude ¹H-NMR analysis.

NMR and HRMS data for the product 9c:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 8.85 (s, 1H), 7.86 (d, *J* = 7.8 Hz, 2H), 7.65 – 7.59 (m, 3H), 7.49 – 7.45 (m, 2H), 7.34 – 7.30 (m, 2H), 7.29 – 7.27 (m, 3H), 7.16 (d, *J* = 7.2 Hz, 2H), 7.04 (t, *J* = 7.2 Hz, 1H), 6.86 (t, *J* = 7.2 Hz, 1H), 6.57 (d, *J* = 7.8 Hz, 1H), 5.83 (d, *J* = 4.8 Hz, 1H), 4.97 (d, *J* = 4.8 Hz, 1H), 2.46 (s, 3H), 2.35 (s, 3H).


¹³C NMR (150 MHz, CDCl₃) δ (ppm): 195.7, 144.8, 141.4, 138.2, 138.1, 137.7, 136.2, 133.6, 132.0, 130.0, 129.6, 128.7, 128.7, 128.0, 126.4, 123.4, 120.7, 120.7, 117.6, 111.9, 99.5, 72.2,

56.3, 21.7, 21.2.

HRMS (ESI) m/z calculated for $C_{31}H_{26}N_2O_3S+Na^+$: 529.1556, found: 529.1556.

(4-chlorophenyl)(2-phenyl-1-tosyl-1,2,3,8-tetrahydropyrrolo[2,3-b]indol-3-yl)methanone

9d



Prepared according to the general procedure to afford **9d** (19.5 mg) in 37% yield as yellow solid, m.p. = 197 – 200 °C. The diastereomeric ratio was determined to be >20:1 by crude 1H -NMR analysis.


NMR and HRMS data for the product 9d:

1H NMR (600 MHz, $CDCl_3$) δ (ppm): 8.85 (s, 1H), 7.81 (d, $J = 9.0$ Hz, 2H), 7.63 (d, $J = 8.4$ Hz, 2H), 7.44 (d, $J = 9.0$ Hz, 2H), 7.38 – 7.28 (m, 8H), 7.07 (t, $J = 7.2$ Hz, 1H), 6.91 (t, $J = 7.8$ Hz, 1H), 6.62 (d, $J = 7.8$ Hz, 1H), 5.83 (d, $J = 4.8$ Hz, 1H), 4.91 (d, $J = 4.8$ Hz, 1H), 2.46 (s, 3H).

^{13}C NMR (150 MHz, $CDCl_3$) δ (ppm): 194.5, 144.9, 141.6, 141.0, 140.3, 137.8, 134.4, 132.0, 130.1, 130.0, 129.1, 129.0, 128.4, 128.0, 126.4, 123.3, 120.9, 120.8, 117.5, 112.0, 99.2, 72.3, 56.2, 21.7.

HRMS (ESI) m/z calculated for $C_{30}H_{23}ClN_2O_3S+Na^+$: 549.1010(^{35}Cl), 550.1044 (^{37}Cl), found: 549.1014, 550.1039.

(2-phenyl-1-tosyl-1,2,3,8-tetrahydropyrrolo[2,3-b]indol-3-yl)(thiophen-2-yl)methanone 9e



Prepared according to the general procedure to afford **9e** (17.9 mg) in 36% yield as yellow solid, m.p. = 197 – 201 °C. The diastereomeric ratio was determined to be >20:1 by crude

¹H-NMR analysis.


NMR and HRMS data for the product 9e:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 8.87 (s, 1H), 7.80 (s, 1H), 7.70 (d, *J* = 4.2 Hz, 1H), 7.64 (d, *J* = 7.8 Hz, 2H), 7.41 – 7.35 (m, 5H), 7.34 – 7.27 (m, 3H), 7.18 – 7.14 (m, 1H), 7.09 (t, *J* = 7.2 Hz, 1H), 6.95 (t, *J* = 7.2 Hz, 1H), 6.86 (d, *J* = 7.8 Hz, 1H), 5.76 (d, *J* = 4.2 Hz, 1H), 4.82 (d, *J* = 4.8 Hz, 1H), 2.43 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 188.6, 145.0, 142.9, 141.7, 140.9, 137.8, 135.0, 132.9, 131.8, 130.1, 129.9, 128.9, 128.3, 128.2, 128.0, 126.5, 123.4, 120.9, 117.5, 112.0, 99.7, 72.9, 57.2, 21.7.


HRMS (ESI) *m/z* calculated for C₂₈H₂₂N₂O₃S₂+H⁺: 499.1145, found: 499.1153.

5.2 General procedure for the oxidation/rearrangement of **9**



The product **9** (0.1 mmol) was dissolved in toluene (1.0 mL). To this solution was added DQ (0.2 mmol). Then the reaction was stirred for 12 hours at 40 °C. Then the mixture was cooled to room temperature and purified by column chromatography on silica gel (petroleum ether/ dichloromethane/ methanol = 150:150:0.5) to afford **10**, which was dried under vacuum and further analyzed by ¹H NMR, ¹³C NMR, HRMS, *etc.*

3,4-diphenyl-2-tosyl-2,3-dihydro-1H-pyrrolo[3,4-c]quinolin-1-one 10a



The reaction provided 26.0 mg of **10a** in 53% yield as yellow solid, m.p. = 248 – 251 °C.

NMR and HRMS data for the product 10a:


¹H NMR (600 MHz, CDCl₃) δ (ppm): 9.05 (d, *J* = 8.4 Hz, 1H), 8.23 (d, *J* = 8.4 Hz, 1H), 7.85 (t, *J* = 8.4 Hz, 1H), 7.75 (t, *J* = 7.2 Hz, 1H), 7.38 – 7.32 (m, 7H), 7.10 – 7.05 (m, 3H), 6.94 –

6.90 (m, 2H), 6.60 – 6.57 (m, 3H), 2.32 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 165.9, 155.7, 148.3, 144.9, 138.8, 137.8, 135.3, 133.5, 131.9, 130.8, 129.9, 129.2, 129.1, 128.5, 128.5, 128.3, 128.2, 128.0, 128.0, 123.5, 121.8, 64.5, 21.6.

HRMS (ESI) m/z calculated for C₃₀H₂₂N₂O₃S+Na⁺: 513.1243, found: 513.1244.

3-(4-chlorophenyl)-4-phenyl-2-tosyl-2,3-dihydro-1H-pyrrolo[3,4-c]quinolin-1-one 10b



The reaction provided 24.7 mg of **10b** in 47% yield as yellow solid, m.p. = 192 – 195 °C.


NMR and HRMS data for the product 10b:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 9.03 (d, *J* = 7.8 Hz, 1H), 8.24 (d, *J* = 8.4 Hz, 1H), 7.86 (t, *J* = 7.2 Hz, 1H), 7.76 (t, *J* = 6.6 Hz, 1H), 7.43 – 7.35 (m, 7H), 7.12 (d, *J* = 8.4 Hz, 2H), 6.89 (d, *J* = 9.0 Hz, 2H), 6.57 (s, 1H), 6.52 (d, *J* = 8.4 Hz, 2H), 2.36 (s, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm): 165.8, 155.5, 148.4, 145.2, 138.3, 137.7, 135.3, 134.3, 132.3, 131.8, 131.0, 129.9, 129.7, 129.4, 129.3, 129.2, 128.6, 128.2, 128.1, 127.9, 123.5, 121.8, 63.7, 21.6.

HRMS (ESI) m/z calculated for C₃₀H₂₁ClN₂O₃S+Na⁺: 547.0854(³⁵Cl), 548.0887 (³⁷Cl), found: 547.0853, 548.0885.

4-phenyl-3-(p-tolyl)-2-tosyl-2,3-dihydro-1H-pyrrolo[3,4-c]quinolin-1-one 10c



The reaction provided 21.2 mg of **10c** in 42% yield as yellow solid, m.p. = 161 – 165 °C.


NMR and HRMS data for the product 10c:

¹H NMR (600 MHz, CDCl₃) δ (ppm): 9.05 (d, *J* = 7.8 Hz, 1H), 8.23 (d, *J* = 7.8 Hz, 1H), 7.86 – 7.82 (m, 1H), 7.75 (t, *J* = 7.2 Hz, 1H), 7.39 – 7.32 (m, 7H), 7.07 (d, *J* = 8.4 Hz, 2H), 6.72 (d, *J* = 7.8 Hz, 2H), 6.57 (s, 1H), 6.47 (d, *J* = 7.8 Hz, 2H), 2.34 (s, 3H), 2.21 (s, 3H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 166.0, 155.7, 148.3, 144.8, 138.9, 138.2, 137.8, 135.4, 131.8, 130.7, 130.5, 129.9, 129.2, 129.1, 129.0, 128.7, 128.4, 128.4, 128.2, 128.1, 123.5, 121.9, 64.4, 21.6, 21.1.

HRMS (ESI) m/z calculated for $\text{C}_{31}\text{H}_{24}\text{N}_2\text{O}_3\text{S}+\text{Na}^+$: 527.1400, found: 527.1400.

4-(4-chlorophenyl)-3-phenyl-2-tosyl-2,3-dihydro-1H-pyrrolo[3,4-c]quinolin-1-one 10d



The reaction provided 23.6 mg of **10d** in 45% yield as yellow solid, m.p. = 224 – 226 °C.


NMR and HRMS data for the product 10d:

^1H NMR (600 MHz, CDCl_3) δ (ppm): 9.05 (dd, $J = 8.4, 1.2$ Hz, 1H), 8.22 (d, $J = 8.4$ Hz, 1H), 7.88 – 7.84 (m, 1H), 7.77 (t, $J = 7.2$ Hz, 1H), 7.34 – 7.30 (m, 6H), 7.13 (t, $J = 7.2$ Hz, 1H), 7.06 (d, $J = 7.8$ Hz, 2H), 6.99 – 6.95 (m, 2H), 6.63 (d, $J = 7.2$ Hz, 2H), 6.56 (s, 1H), 2.33 (s, 3H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 165.7, 154.3, 148.3, 145.0, 138.5, 136.2, 135.5, 135.3, 133.4, 132.2, 131.0, 129.8, 129.6, 129.4, 129.2, 128.7, 128.6, 128.2, 128.0, 123.6, 121.9, 64.4, 21.6.

HRMS (ESI) m/z calculated for $\text{C}_{30}\text{H}_{21}\text{ClN}_2\text{O}_3\text{S}+\text{Na}^+$: 547.0854(^{35}Cl), 548.0887 (^{37}Cl), found: 547.0851, 548.0877.

3-phenyl-4-(thiophen-2-yl)-2-tosyl-2,3-dihydro-1H-pyrrolo[3,4-c]quinolin-1-one 10e



The reaction provided 23.8 mg of **10e** in 48% yield as yellow solid, m.p. = 243 – 245 °C.

NMR and HRMS data for the product 10e:

^1H NMR (600 MHz, CDCl_3) δ (ppm): 9.02 (d, $J = 8.4$ Hz, 1H), 8.18 (d, $J = 7.8$ Hz, 1H), 7.85 – 7.81 (m, 1H), 7.72 – 7.69 (m, 1H), 7.47 (d, $J = 2.4$ Hz, 1H), 7.39 (dd, $J = 5.4, 1.2$ Hz, 1H), 7.30 (d, $J = 8.4$ Hz, 2H), 7.24 – 7.20 (m, 1H), 7.13 – 7.10 (m, 2H), 7.06 – 7.02 (m, 3H), 6.98 (d,

$J = 7.8$ Hz, 2H), 6.75 (s, 1H), 2.32 (s, 3H).

^{13}C NMR (150 MHz, CDCl_3) δ (ppm): 165.6, 148.2, 144.9, 141.3, 136.6, 135.3, 133.6, 132.8, 131.0, 129.5, 129.4, 129.3, 129.2, 129.0, 128.9, 128.4, 127.9, 127.7, 123.5, 121.6, 64.6, 21.6.

HRMS (ESI) m/z calculated for $\text{C}_{28}\text{H}_{20}\text{N}_2\text{O}_3\text{S}_2 + \text{Na}^+$: 519.0808, found: 519.0802.

5.3 Proposed reaction mechanism








Figure S1. Proposed mechanism.

6. Crystal Data and Structure Refinement





Identification code	3i
Empirical formula	C ₃₀ H ₂₃ ClN ₂ O ₃ S
Formula weight	527.01
Temperature/K	298.0
Crystal system	monoclinic
Space group	P2 ₁ /n
a/Å	12.9731(6)
b/Å	15.1155(6)
c/Å	13.3582(6)
α/°	90
β/°	94.384(2)
γ/°	90
Volume/Å ³	2611.8(2)
Z	4
ρ _{calc} /cm ³	1.340
μ/mm ⁻¹	0.261
F(000)	1096.0
Crystal size/mm ³	0.35 × 0.18 × 0.11
Radiation	MoKα (λ = 0.71073)
2θ range for data collection/°	4.076 to 55.09
Index ranges	-16 ≤ h ≤ 16, -18 ≤ k ≤ 19, -17 ≤ l ≤ 17
Reflections collected	57430
Independent reflections	6009 [R _{int} = 0.1401, R _{sigma} = 0.0652]
Data/restraints/parameters	6009/0/335
Goodness-of-fit on F ²	1.013
Final R indexes [I ≥ 2σ (I)]	R ₁ = 0.0518, wR ₂ = 0.1069
Final R indexes [all data]	R ₁ = 0.1145, wR ₂ = 0.1301
Largest diff. peak/hole / e Å ⁻³	0.20/-0.36



10a (CCDC 2118408)

Identification code	10a
Empirical formula	C ₃₀ H ₂₂ N ₂ O ₃ S
Formula weight	490.55
Temperature/K	150.0
Crystal system	orthorhombic
Space group	Pna2 ₁
a/Å	21.023(3)
b/Å	12.4076(16)
c/Å	18.781(3)
α/°	90
β/°	90
γ/°	90
Volume/Å ³	4899.0(13)
Z	8
ρ _{calc} /cm ³	1.330
μ/mm ⁻¹	0.168
F(000)	2048.0
Crystal size/mm ³	0.32 × 0.18 × 0.16
Radiation	MoKα (λ = 0.71073)
2θ range for data collection/°	3.812 to 55.114
Index ranges	-23 ≤ h ≤ 27, -16 ≤ k ≤ 14, -24 ≤ l ≤ 21
Reflections collected	43968
Independent reflections	10630 [R _{int} = 0.0676, R _{sigma} = 0.0586]
Data/restraints/parameters	10630/1/651
Goodness-of-fit on F ²	1.017
Final R indexes [I ≥ 2σ (I)]	R ₁ = 0.0422, wR ₂ = 0.0929
Final R indexes [all data]	R ₁ = 0.0583, wR ₂ = 0.1018
Largest diff. peak/hole / e Å ⁻³	0.19/-0.33
Flack parameter	0.46(4)



Identification code	10e
Empirical formula	C ₂₈ H ₂₀ N ₂ O ₃ S ₂
Formula weight	496.58
Temperature/K	185.0
Crystal system	triclinic
Space group	P-1
a/Å	11.4722(9)
b/Å	11.6024(9)
c/Å	11.8100(11)
α/°	112.336(3)
β/°	91.537(3)
γ/°	112.501(3)
Volume/Å ³	1315.76(19)
Z	2
ρ _{calc} /cm ³	1.253
μ/mm ⁻¹	0.233
F(000)	516.0
Crystal size/mm ³	0.43 × 0.35 × 0.09
Radiation	MoKα (λ = 0.71073)
2θ range for data collection/°	3.924 to 55.142
Index ranges	-14 ≤ h ≤ 14, -14 ≤ k ≤ 14, -15 ≤ l ≤ 15
Reflections collected	29591
Independent reflections	6044 [R _{int} = 0.0948, R _{sigma} = 0.0721]
Data/restraints/parameters	6044/0/321
Goodness-of-fit on F ²	1.028
Final R indexes [I >= 2σ (I)]	R ₁ = 0.0503, wR ₂ = 0.1188
Final R indexes [all data]	R ₁ = 0.0841, wR ₂ = 0.1357
Largest diff. peak/hole / e Å ⁻³	0.40/-0.47

7. References and Notes

- 1 (a) E. Krell, *Handbook of Laboratory Distillation*, Elsevier Publishing Company: Amsterdam-London-New York, 1963; (b) M. J. Rosengart, *The Technique of Distillation and Rectification in the Laboratory*, VEB Verlag Technik: Berlin, 1954; (c) F. Stage, *Angew. Chem.*, 1947, **19**, 175.
- 2 K. Moriyama, K. Ishida, H. Togo, *Chem. Common.*, 2015, **51**, 2273.
- 3 S. K. Chittimalla and C. Bandi, *RSC Adv.*, 2013, **3**, 13663.

8. NMR Spectra

